AlphaOS

Coverage building

TAK has basic price and filing data (45% intelligence coverage), but earnings analysis, financial metrics, and proprietary signals are still building. Explore a peer with deeper coverage below.

Deeper coverage nearby

Intelligence coverage: 45%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

TAK

TAKEDA PHARMACEUTICAL CO LTD

Healthcare · Drug Manufacturers—Specialty & Generic

$18.51Sep 29, 2026

AI confidence 50% · refreshes every 15s during session

Investment Snapshot

Limited proprietary earnings coverage for TAK yet — signals will sharpen as filings and earnings are ingested.

Pipeline evidence · 79d ago

TAK's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on TAK.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest Intelligence

Updated

What happened recently for TAKEDA PHARMACEUTICAL CO LTD (TAK) — events, not interpretation.

Event
Last session September 29, 2026 at $18.51.
Source
Market data

Research & analysis only — not investment advice.

Industry & ETF context

Industry blend 62
  • Primary industry Drug Manufacturers—Specialty & Generic scores 62/100 (Early Recovery cycle, Strong momentum).

AlphaOS industries

Drug Manufacturers—Specialty & Generic
Primary
Score 62Early RecoveryStrong momentum

Investment snapshot

TAKEDA PHARMACEUTICAL CO LTD

TAK's opportunity score
Upgrade to Premium
Analysis confidence: 50%

TAK's AI investment thesis

Upgrade to Premium for TAK's full multi-agent investment thesis.

Create free account

Free accounts see more of this; Premium sees all of it.

50% confidence

Intelligence layer

Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity

PricesFinancialsFilingsFiling insightsEarningsEarnings AITranscriptsTechnicalOpportunityResearch
  • →Filing signal: Potential insider selling

Strengthen intelligence

  • · Pull SEC financial metrics (revenue, margins)
  • · Sync IR earnings catalog for release/transcript data
  • · Fetch earnings call transcript for CEO commentary

Latest price

$18.51

Market cap

$28.83B

Profitable

—

Net income

—

Analyst ratings

Loading Wall Street consensus…

Earnings intelligence

Full earnings center

Loading earnings intelligence…

Technical intelligence

Building technical intelligence snapshot — check back shortly.

Loading market context…

Price & volume

0 trading days

No price history. Sync market data to load charts.

Filing insights

Loading SEC filing intelligence…

Competitive landscape

Recent SEC filings

Filings tab

No filings ingested yet.

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Healthcare · Drug Manufacturers—Specialty & Generic

Investment Snapshot above is the primary AlphaOS analysis for TAKEDA PHARMACEUTICAL CO LTD — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Industry:
Drug Manufacturers—Specialty & Generic
Market cap:
$28.83B

TAK earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow TAKEDA PHARMACEUTICAL CO LTD through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Themes

TAKEDA PHARMACEUTICAL CO LTD (TAK) in AlphaOS research

Related & Connected

Related

Related stock research

Connected companies and research pages from the AlphaOS knowledge graph.